sellWeak cluster of 410b5-1 plan
Jessica Snow sold $11k of TSVT
Chief Operating Officer at 2seventy bio, Inc.. 2,298 shares at an average of $4.95, traded Mar 17, 2025, filed Mar 19, 2025.
Warning score
15Value
$11k
2,298 shares
Holdings after
254,193
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleCOO
- 0Trade size$11k at market
- 0Share of holdings soldSold 0.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-25-002605, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,298 | $4.95 | $11k | 254,193 | Mar 19, 2025 |
Related signals
Other insiders at 2seventy bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | 2seventy bio, Inc. | Victoria Eatwell Chief Financial Officer | $13k 2,592 shares | -1% | |
| 45Moderate | 2seventy bio, Inc. | William D Baird III President and CEO | $25k 5,092 shares | -0% | |
| 72Notable | 2seventy bio, Inc. | Kynam Global Healthcare Master Fund, LP owner | $80M 16,238,047 shares | -273% | |
| 50Moderate | 2seventy bio, Inc. | William D Baird III President and CEO | $95k 32,481 shares | -4% | |
| 37Weak | 2seventy bio, Inc. | Victoria Eatwell Chief Financial Officer | $3,244 1,110 shares | -0% | |
| 43Moderate | 2seventy bio, Inc. | Nick Leschly director | $255k 86,870 shares | -7% | |
| 10Weak | 2seventy bio, Inc. | Jessica Snow See Remarks | $18k 6,300 shares | -4% | |
| 0Weak | 2seventy bio, Inc. | Jessica Snow See Remarks | $7,393 2,287 shares | -1% | |
| 20Weak | TSVTsell 2seventy bio, Inc. | Marcela V. Maus director | $13k 3,900 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.